1. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
- Author
-
McMurray JJ, Dunselman P, Wedel H, Cleland JG, Lindberg M, Hjalmarson A, Kjekshus J, Waagstein F, Apetrei E, Barrios V, Böhm M, Kamenský G, Komajda M, Mareev V, and Wikstrand J
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Female, Fluorobenzenes adverse effects, Follow-Up Studies, Heart Failure diagnosis, Hospitalization trends, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Internationality, Male, Middle Aged, Prospective Studies, Pyrimidines adverse effects, Rosuvastatin Calcium, Sulfonamides adverse effects, Treatment Outcome, Ubiquinone antagonists & inhibitors, Ubiquinone blood, Fluorobenzenes therapeutic use, Heart Failure blood, Heart Failure drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Pyrimidines therapeutic use, Sulfonamides therapeutic use, Ubiquinone analogs & derivatives
- Abstract
Objectives: The purpose of this study was to determine whether coenzyme Q₁₀ is an independent predictor of prognosis in heart failure., Background: Blood and tissue concentrations of the essential cofactor coenzyme Q₁₀ are decreased by statins, and this could be harmful in patients with heart failure., Methods: We measured serum coenzyme Q₁₀ in 1,191 patients with ischemic systolic heart failure enrolled in CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) and related this to clinical outcomes., Results: Patients with lower coenzyme Q₁₀ concentrations were older and had more advanced heart failure. Mortality was significantly higher among patients in the lowest compared to the highest coenzyme Q₁₀ tertile in a univariate analysis (hazard ratio: 1.50, 95% confidence interval: 1.04 to 2.6, p = 0.03) but not in a multivariable analysis. Coenzyme Q₁₀ was not an independent predictor of any other clinical outcome. Rosuvastatin reduced coenzyme Q₁₀ but there was no interaction between coenzyme Q₁₀ and the effect of rosuvastatin., Conclusions: Coenzyme Q₁₀ is not an independent prognostic variable in heart failure. Rosuvastatin reduced coenzyme Q₁₀, but even in patients with a low baseline coenzyme Q₁₀, rosuvastatin treatment was not associated with a significantly worse outcome. (Controlled Rosuvastatin Multinational Study in Heart Failure [CORONA]; NCT00206310)., (Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF